Both genetic and pharmacological targeting of FOXM1 markedly suppressed CTCL cell growth and proliferation by inducing programmed cell death (apoptosis and autophagy) via reactive oxygen species (ROS) generation. The gene discussed is FOXM1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.